Croissy-Beaubourg and Montpellier, on may 12, 2017 – 8: 00 CEST – THERADIAG (ISIN : FR0004197747, Ticker : ALTER, eligible PEA-PME), a company specialized in the in vitro diagnostic and theranostic, today announced the success of a capital increase for the benefit of a category of beneficiaries, carried out by accelerated building of an order book. The Company has placed 1 749 563 new shares of a nominal value of eur 1.70 at a price of 2.30, issuance premium included, for a total amount of 4 023 994,90 euros representing 20,21% of the share capital post-transaction of the Company.
Download the free guide
Boost your gains
As a guideline, the participation of a shareholder holding 1% of the share capital of the Company prior to the issuance will be increased to 0.8%.
The funds raised will allow Theradiag to facilitate and accelerate its international development and marketing of ranges of auto‑immunity, allergy and theranostic. Michel Finance, ceo of Theradiag, comments : “The success of this capital increase provides us with an ownership structure strengthened, and the necessary funds, in particular for the placing on the european market in the coming months, the BioCLIA® that will allow us to accelerate the development of the Business Unit in vitro Diagnostic use. We would like to thank our new shareholders for their confidence and support.”
The operation was implemented by decision of the Board of directors of may 11, 2017, and the Director-General dated 11 may 2017, in accordance to the delegation that he had been granted by the 15th resolution approved by the combined General Meeting of shareholders of 27 April 2017 and at a price representing a discount of 15.6% compared to the average weighted by the volumes of the last five stock market sessions preceding the decision of the Board.
The capital increase is performed by issuing common shares without preferential subscription right for the benefit of a category of beneficiaries. The settlement-delivery of the new shares issued within the framework of the capital increase and their listing on the market Alternext Paris to Euronext Paris is expected on 17 may 2017. The new shares will bear dividend rights common and will be admitted to trading on the Alternext Paris under ISIN code FR0004197747 – ALTER. Social capital, Theradiag will be composed of 8 654 944 shares at the end of the settlement.
And post-capital increase and disposal of shares by the investment fund Truffle Capital is the management company, the distribution of the share capital of the Company has changed significantly. Post-transaction, HOB’s Capital holds as well 8,56% of the total capital and the free float is 91,44%.
EuroLand Corporate has stepped in as board of the corporation.
In accordance with the provisions of article 211-3 of the general Regulation of the Autorité des marchés financiers, the offer of shares of the Company within the framework of this capital increase made for the benefit of a category of beneficiaries determined, did not result in a prospectus submitted to the visa of the Autorité des marchés financiers. Detailed information about the Company, including relating to its business, its results and the risk factors corresponding, are included in the annual financial report for the fiscal year ended December 31, 2016, which may be consulted, as well as other regulated information and all press releases of the Company, on its website (www.theradiag.com).
Next press release financial :
Sales for the half year 2017 : Tuesday, July 25, 2017
About Theradiag
Strong of its expertise in the distribution, development and manufacturing of tests for in vitro diagnostics, Theradiag innovates and develops tests and theranostic (alliance of treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag participates in the development of ” personalized medicine “, promoting the individualization of treatments, the extent of their effectiveness, and the prevention of resistance. Theradiag markets the range of LISA TRACKER®, CE mark, a complete solution of diagnostic multiparametric for the support of patients with autoimmune diseases treated with biotherapies. Through its subsidiary Prestizia, Theradiag is also developing new markers of diagnosis through the platform micrornas for the detection and monitoring of cancer of the rectum and HIV/AIDS. The company is based in Marne‑la‑Vallée and Montpellier, and has over 75 employees.
For more information about Theradiag, please visit our web site : www.theradiag.com
Download the free guide
Boost your gains
